Home Healthcare Pharmaceuticals Radioligand Therapy Market

Radioligand Therapy Market Size, Share & Trends Analysis Report By Isotope (Lutetium-177 (Lu-177), Actinium-225 (Ac-225), Iodine-131 (I-131), Other Isotopes), By Target (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor), By Indication (Prostate Cancer, Neuroendocrine Tumours (NETs), Others), By End-User (Hospitals, Ambulatory Surgical Centers, Cancer Treatment Centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Radioligand Therapy Market, By Isotope 2022-2034 (USD MILLION/ Units)
    1. Lutetium-177 (Lu-177)
    2. Actinium-225 (Ac-225)
    3. Iodine-131 (I-131)
    4. Other Isotopes
  2. Radioligand Therapy Market, By Target 2022-2034 (USD MILLION/ Units)
    1. Prostate-Specific Membrane Antigen
    2. Ki 67 Expression and Grading
    3. Cytochrome P450 17A1 Inhibitor
  3. Radioligand Therapy Market, By Indication 2022-2034 (USD MILLION/ Units)
    1. Prostate Cancer
    2. Neuroendocrine Tumours (NETs)
    3. Others
  4. Radioligand Therapy Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Ambulatory Surgical Centers
    3. Cancer Treatment Centers
    4. Others
  5. Regional Radioligand Therapy Market
    1. North America
      1. North America Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      2. North America Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      3. North America Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      4. North America Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
      5. U.S.
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      6. Canada
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
    2. Europe
      1. Europe Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      2. Europe Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      3. Europe Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      4. Europe Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
      5. U.K.
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      6. Germany
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      7. France
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      8. Spain
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      9. Italy
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      10. Russia
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      11. Nordic
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      12. Benelux
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      13. Rest of Europe
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
    3. APAC
      1. APAC Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      2. APAC Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      3. APAC Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      4. APAC Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
      5. China
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      6. Korea
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      7. Japan
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      8. India
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      9. Australia
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      10. Taiwan
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      11. South East Asia
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      12. Rest of Asia-Pacific
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
    4. Middle East and Africa
      1. Middle East and Africa Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      2. Middle East and Africa Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      3. Middle East and Africa Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      4. Middle East and Africa Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
      5. UAE
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      6. Turkey
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      7. Saudi Arabia
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      8. South Africa
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      9. Egypt
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      10. Nigeria
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      11. Rest of MEA
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
    5. LATAM
      1. LATAM Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      2. LATAM Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      3. LATAM Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      4. LATAM Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
      5. Brazil
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      6. Mexico
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      7. Argentina
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      8. Chile
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      9. Colombia
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
      10. Rest of LATAM
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
        5. Prostate-Specific Membrane Antigen
        6. Ki 67 Expression and Grading
        7. Cytochrome P450 17A1 Inhibitor
        8. Prostate Cancer
        9. Neuroendocrine Tumours (NETs)
        10. Others
        11. Hospitals
        12. Ambulatory Surgical Centers
        13. Cancer Treatment Centers
        14. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.